– USA, CA – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the appointment of Dr. Scott Braunstein, M.D. to its board of directors.
Dr. Braunstein, an accomplished leader with over 20 years of industry experience, has expertise and experience in governing, leading, and investing in biopharmaceutical companies.
“It is a great privilege to welcome Scott to our board of directors,” said CEO, Dr. Rachel Haurwitz. “We believe his extensive experience in financing and executing on the development of novel therapeutics will be especially valuable to us as we advance our chRDNA-edited allogeneic cell therapies and continue to build the company.”
About Dr. Scott Braunstein
Dr. Braunstein currently serves as CEO and board member of Marinus Pharmaceuticals, a company dedicated to the development of innovative therapeutics that treat rare seizure disorders. He has held the role of operating partner at Aisling Capital since 2015. Before joining Marinus Pharmaceuticals, Dr. Braunstein previously served as chief strategy officer and COO at Pacira Pharmaceuticals, Inc.
Earlier in his career, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director on the U.S. equity team and as portfolio manager of the J.P. Morgan Global Healthcare Fund.
Dr. Braunstein also serves as a board member of Trevena, Inc. and Constellation Pharmaceuticals, which recently received a tender offer from MorphoSys AG to acquire all of the outstanding shares of Constellation’s common stock in cash. He previously served as a board member of Ziopharm Oncology, Inc., Esperion Therapeutics, Inc., and Protara Therapeutics, Inc.
“As a pioneer in CRISPR genome editing, Caribou has a rich pipeline of promising next-generation cancer-targeted cell therapies that are designed to enhance persistence and unlock the broad potential of allogeneic cell therapies,” said Dr. Braunstein. “I look forward to collaborating with the team as they progress in the clinic and pursue their goals to transform the landscape of genome-edited cell therapies and improve outcomes for patients.”
Dr. Braunstein began his career as a physician at the Summit Medical Group and as an assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He received his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors for both clinically evaluated targets as well as new targets.
For more information: https://www.cariboubio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
